Canon Medical Systems USA has received clearance from the U.S. Food and Drug Administration (FDA) for its Alphenix 4D CT with Aquilion One/Insight Edition interventional imaging system.
The system is a hybrid of the company’s Alphenix 4D CT angiography system and its flagship Aquilion One/Insight Edition CT scanner. The integrated multimodal system is designed for use in interventional radiology and enables diagnosis, planning, treatment, and verification in one room, thereby eliminating the need for patient transfer between departments, according to the firm.
Canon is on schedule to make the system commercially available in the summer of 2026. Alphenix 4D CT with Aquilion One/Insight Edition will be on display at RSNA 2025 in Chicago, the company added.
![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&dpr=2&fit=crop&h=167&q=70&w=250)
